Cue Biopharma (CUE) CFO James Ahlers Receives RSUs & Options

What Happened
James M. Ahlers, Chief Financial Officer of Cue Biopharma (CUE), was granted compensation awards on July 30, 2026: 25,500 restricted stock units (RSUs) and a derivative award covering 51,000 shares (stock option). Both awards were granted at $0.00 (no cash paid) and are compensation grants rather than open-market purchases or sales.

Key Details

• Transaction date: July 30, 2026. Form 4 filed Aug 3, 2026 (appears timely — filed within two business days).
• RSU grant: 25,500 shares @ $0.00 (footnote F1). Vesting: equal quarterly installments over four years from July 30, 2026, subject to continued service.
• Option/derivative grant: 51,000 shares @ $0.00 (footnote F2). Becomes exercisable in equal quarterly installments over four years from July 30, 2026, subject to continued service.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Transaction code: A = Award/Grant. No sale, exercise, tax-withholding, or 10b5-1 plan noted in the provided details.

Context
These are standard equity compensation awards that vest over time and are contingent on continued employment. They are not immediate purchases or sales and do not by themselves indicate the insider is buying or selling shares in the market. The derivative entry represents an option grant that will become exercisable in installments rather than an exercised option.